All Stories

  1. Correction of anemia by dapagliflozin in patients with type 2 diabetes

    Article • Journal of Diabetes and its Complications, December 2020, Elsevier

    Bergur Stefansson

  2. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

    Article • Circulation, November 2020, Wolters Kluwer Health

    Bergur Stefansson

  3. Dapagliflozin in Patients with Chronic Kidney Disease

    Article • New England Journal of Medicine, October 2020, New England Journal of Medicine (NEJM/MMS)

    Bergur Stefansson

  4. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Article • Nephrology Dialysis Transplantation, August 2020, Oxford University Press (OUP)

    Bergur Stefansson, Dr Frederik Persson

  5. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

    Article • Nephrology Dialysis Transplantation, February 2020, Oxford University Press (OUP)

    Bergur Stefansson

  6. The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis

    Article • Diabetes Obesity and Metabolism, December 2019, Wiley

    Bergur Stefansson

  7. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials

    Article • Journal of Diabetes and its Complications, October 2019, Elsevier

    Bergur Stefansson

  8. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, p...

    Article • The Lancet Diabetes & Endocrinology, June 2019, Elsevier

    Bergur Stefansson

  9. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers

    Article • Nephrology Dialysis Transplantation, April 2019, Oxford University Press (OUP)

    Bergur Stefansson

  10. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

    Article • Diabetes Obesity and Metabolism, December 2018, Wiley

    Bergur Stefansson

  11. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus

    Article • BMC Nephrology, June 2018, Springer Science + Business Media

    Bergur Stefansson

  12. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

    Article • Nephrology Dialysis Transplantation, May 2018, Oxford University Press (OUP)

    Bergur Stefansson

  13. Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers

    Article • British Journal of Clinical Pharmacology, May 2017, Wiley

    Bergur Stefansson

  14. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

    Article • European Heart Journal, April 2017, Oxford University Press (OUP)

    Bergur Stefansson

  15. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions

    Article • Clinical Pharmacology in Drug Development, March 2017, Wiley

    Bergur Stefansson

  16. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis

    Article • Clinical Journal of the American Society of Nephrology, June 2016, American Society of Nephrology

    Dr Geoffrey A Block, Bergur Stefansson

  17. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

    Article • Diabetologia, June 2016, Springer Science + Business Media

    Bergur Stefansson

  18. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients

    Article • BMC Nephrology, July 2015, Springer Science + Business Media

    Bergur Stefansson

  19. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors

    Article • Cardiovascular Diabetology, April 2015, Springer Science + Business Media

    Bergur Stefansson

  20. Intradialytic Hypotension and Risk of Cardiovascular Disease

    Article • Clinical Journal of the American Society of Nephrology, November 2014, American Society of Nephrology

    Bergur Stefansson

  21. Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration

    Article • Nephron Extra, March 2012, Karger Publishers

    Bergur Stefansson

  22. Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

    Article • Nephron Extra, January 2011, Karger Publishers

    Bergur Stefansson

  23. Melanocortin 1 Receptor Agonists Reduce Proteinuria

    Article • Journal of the American Society of Nephrology, May 2010, American Society of Nephrology

    Bergur Stefansson